<span item_type="fundamental" item_id="5d19b210c0558cf4fe4d30b25f1f4754" counter_id="ST/US/BCAX" env="prod"></span><span item_type="announcement" item_id="548590335536596481" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.5, beating the estimate of USD -0.535.</p><p></p><h3>Cash Position</h3><ul><li>As of June 30, 2025, Bicara Therapeutics Inc. had cash and cash equivalents of $436.6 million, compared to $489.7 million as of December 31, 2024. The company expects that its existing cash and cash equivalents will fund operations into the first half of 2029.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm"></span></li></ul><h3>Research and Development Expenses</h3><ul><li>Research and development expenses were $24.8 million for the second quarter of 2025, compared to $15.8 million for the second quarter of 2024. The increase was primarily due to additional costs associated with the initiation of the FORTIFI-HN01 pivotal Phase <sup>2</sup>⁄<sub>3</sub> clinical trial, ongoing Phase 1/1b clinical trials to advance ficerafusp alfa, and an increase in personnel costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm"></span></li></ul><h3>General and Administrative Expenses</h3><ul><li>General and administrative expenses were $7.2 million for the second quarter of 2025, compared to $3.9 million for the second quarter of 2024. The increase was primarily due to additional personnel costs and professional fees to support the advancement of clinical trials and operations as a public company.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss totaled $27.4 million for the second quarter of 2025, compared to $17.0 million for the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Bicara Therapeutics Inc. expects that its existing cash and cash equivalents will fund operations into the first half of 2029. The company anticipates presenting data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients by Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm"></span></li></ul>

Bicara Therapeutics | 8-K: FY2025 Q2 EPS Beats Estimate at USD -0.5